Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) announced results showing significant effects of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model.
Treatment with Aramchol resulted in statistically significant improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone, the gold standard ... Full story available on Benzinga.com